1. Home
  2. APLM vs PT Comparison

APLM vs PT Comparison

Compare APLM & PT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • PT
  • Stock Information
  • Founded
  • APLM 2016
  • PT 2012
  • Country
  • APLM United States
  • PT China
  • Employees
  • APLM N/A
  • PT N/A
  • Industry
  • APLM Blank Checks
  • PT Computer Software: Programming Data Processing
  • Sector
  • APLM Finance
  • PT Technology
  • Exchange
  • APLM Nasdaq
  • PT Nasdaq
  • Market Cap
  • APLM 6.9M
  • PT 15.2M
  • IPO Year
  • APLM N/A
  • PT 2018
  • Fundamental
  • Price
  • APLM $6.56
  • PT $0.92
  • Analyst Decision
  • APLM
  • PT
  • Analyst Count
  • APLM 0
  • PT 0
  • Target Price
  • APLM N/A
  • PT N/A
  • AVG Volume (30 Days)
  • APLM 6.5K
  • PT 10.6K
  • Earning Date
  • APLM 08-13-2025
  • PT 07-07-2025
  • Dividend Yield
  • APLM N/A
  • PT N/A
  • EPS Growth
  • APLM N/A
  • PT N/A
  • EPS
  • APLM N/A
  • PT N/A
  • Revenue
  • APLM $198,000.00
  • PT $4,814,566.00
  • Revenue This Year
  • APLM $415.15
  • PT N/A
  • Revenue Next Year
  • APLM N/A
  • PT N/A
  • P/E Ratio
  • APLM N/A
  • PT N/A
  • Revenue Growth
  • APLM N/A
  • PT N/A
  • 52 Week Low
  • APLM $4.47
  • PT $0.76
  • 52 Week High
  • APLM $35.98
  • PT $1.15
  • Technical
  • Relative Strength Index (RSI)
  • APLM 53.03
  • PT 49.78
  • Support Level
  • APLM $6.21
  • PT $0.89
  • Resistance Level
  • APLM $6.80
  • PT $0.95
  • Average True Range (ATR)
  • APLM 0.50
  • PT 0.06
  • MACD
  • APLM 0.02
  • PT 0.00
  • Stochastic Oscillator
  • APLM 77.22
  • PT 72.29

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.

Share on Social Networks: